Get started
Author

Kim M. Hemsley

Observed names: Hemsley, K, Hemsley, Kim M., K HEMSLEY, K Hemsley, K. M. Hemsley, K.M. Hemsley, KM Hemsley, Kim Hemsley, Kim M Hemsley
Observed institutions: South Australia Pathology, Flinders University, Women's and Children's Hospital, Flinders Medical Centre, Women's and Children's Health Network, Adelaide Institute for Sleep Health, South Australian Health and Medical Research Institute, Adelaide University, The University of Adelaide
ORCID: 0000-0003-1038-9884
Observed ORCID: 0000-0003-1038-9884
OpenAlex ID: A5017858985
Endo‐lysosomal and autophagic dysfunction: a driving factor in Alzheimer's disease?
2016 · Lauren S. Whyte, Adeline A. Lau, et al. · Journal of Neurochemistry · 149
PDF
Functional correction of CNS lesions in an MPS-IIIA mouse model by intracerebral AAV-mediated delivery of sulfamidase and SUMF1 genes
2007 · Alessandro Fraldi, Kim Hemsley, et al. · Human Molecular Genetics · 129
Characterization of a C57BL/6 congenic mouse strain of mucopolysaccharidosis type IIIA
2006 · Allison C. Crawley, Briony L. Gliddon, et al. · Brain Research · 107
Reduction in open field activity in the absence of memory deficits in the AppNL−G−F knock-in mouse model of Alzheimer’s disease
2017 · Lauren S. Whyte, Kim M. Hemsley, et al. · Behavioural Brain Research · 87
Injection of recombinant human sulfamidase into the CSF via the cerebellomedullary cistern in MPS IIIA mice
2006 · Kim M. Hemsley, Barbara King, et al. · Molecular Genetics and Metabolism · 86
Open field locomotor activity and anxiety-related behaviors in mucopolysaccharidosis type IIIA mice
2008 · Adeline A. Lau, Allison C. Crawley, et al. · Behavioural Brain Research · 79
Development of motor deficits in a murine model of mucopolysaccharidosis type IIIA (MPS-IIIA)
2004 · K HEMSLEY, J HOPWOOD · Behavioural Brain Research · 79
Effect of high dose, repeated intra‐cerebrospinal fluid injection of sulphamidase on neuropathology in mucopolysaccharidosis type IIIA mice
2008 · K. M. Hemsley, H. Beard, et al. · Genes Brain & Behavior · 76
Intracerebral injection of sulfamidase delays neuropathology in murine MPS-IIIA
2004 · Peter S Savas, Kim M Hemsley, et al. · Molecular Genetics and Metabolism · 67
Examination of intravenous and intra‐CSF protein delivery for treatment of neurological disease
2009 · Kim M. Hemsley, Amanda J. Luck, et al. · European Journal of Neuroscience · 66
Effect of cisternal sulfamidase delivery in MPS IIIA Huntaway dogs—A proof of principle study
2009 · Kim M. Hemsley, Elizabeth J. Norman, et al. · Molecular Genetics and Metabolism · 60
Enzyme replacement reduces neuropathology in MPS IIIA dogs
2011 · Allison C. Crawley, Neil Marshall, et al. · Neurobiology of Disease · 54
An animal model of extrapyramidal side effects induced by antipsychotic drugs: relationship with D2 dopamine receptor occupancy
2001 · Ann D. Crocker, Kim M. Hemsley · Progress in Neuro-Psychopharmacology and Biological Psychiatry · 52
Axonal dystrophy in the brain of mice with Sanfilippo syndrome
2017 · Helen Beard, Sofia Hassiotis, et al. · Experimental Neurology · 43
A Preclinical Study Evaluating AAVrh10-Based Gene Therapy for Sanfilippo Syndrome
2016 · Leanne K. Winner, Helen Beard, et al. · Human Gene Therapy · 43
Impact of high-dose, chemically modified sulfamidase on pathology in a murine model of MPS IIIA
2011 · Tina Rozaklis, Helen Beard, et al. · Experimental Neurology · 42
Allogeneic stem cell transplantation does not improve neurological deficits in mucopolysaccharidosis type IIIA mice
2010 · Adeline A. Lau, Hanan Hannouche, et al. · Experimental Neurology · 33
AAVrh10 Vector Corrects Disease Pathology in MPS IIIA Mice and Achieves Widespread Distribution of SGSH in Large Animal Brains
2019 · Michaël Hocquemiller, Kim M. Hemsley, et al. · Molecular Therapy — Methods & Clinical Development · 32
PDF
Delivery of recombinant proteins via the cerebrospinal fluid as a therapy option for neurodegenerative lysosomal storage diseases
2009 · K.M. Hemsley, J.J. Hopwood · International Journal of Clinical Pharmacology and Therapeutics · 30
Validation of a heparan sulfate-derived disaccharide as a marker of accumulation in murine mucopolysaccharidosis type IIIA
2005 · B KING, P SAVAS, et al. · Molecular Genetics and Metabolism · 30
Determination of the role of injection site on the efficacy of intra-CSF enzyme replacement therapy in MPS IIIA mice
2015 · Helen Beard, Amanda J. Luck, et al. · Molecular Genetics and Metabolism · 29
Changes in Muscle Tone Are Regulated by D1 and D2 Dopamine Receptors in the Ventral Striatum and D1 Receptors in the Substantia Nigra
2001 · K Hemsley · Neuropsychopharmacology · 29
Delivery of therapeutic protein for prevention of neurodegenerative changes: Comparison of different CSF-delivery methods
2014 · Neil R. Marshall, Sofia Hassiotis, et al. · Experimental Neurology · 28
Treatment of canine fucosidosis by intracisternal enzyme infusion
2011 · Gauthami S. Kondagari, Barbara M. King, et al. · Experimental Neurology · 28
Neonatal Bone Marrow Transplantation in MPS IIIA Mice
2012 · Adeline A Lau, N. Jannah Shamsani, et al. · JIMD Reports · 27
Works count: 118
Citation count: 2,120
H-index: 27
I10-index: 54
Year
Topic
Type